A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

• Sponsor: Qilu Pharmaceutical Co., Ltd. (Industry)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05829616
• Collaborator: (none)
• Enrollment: 50
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 25.4
• Patients Per Site Per Month: 2

Study Details

Study Description

Brief Summary

This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Advanced Solid Tumor	Drug: QLS12004	Phase 1

Detailed Description

This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.The frequency of administration and the dose to be administered in subsequent clinical studies will be determined based on a combination of preliminary data.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 50 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Initial Antitumor Activity of QLS12004 in Patients With Advanced Solid Tumors
• Anticipated Study Start Date: Apr 17, 2023
• Anticipated Primary Completion Date: May 30, 2024
• Anticipated Study Completion Date: May 30, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: QLS12004 Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.	Drug: QLS12004; Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.

Outcome Measures

Primary Outcome Measures

1. AEs, TEAEs, TRAEs, SAEs [up to 2 years]

   Incidence, severity and relevance to the trial drug of adverse events (AEs), treatment-related adverse events (TEAEs), treatment-related adverse events (TRAEs) and serious adverse events (SAEs)

2. DLT [Up to 21 days after the first dose]

   Dose-limiting toxicity

3. MTD [Up to 21 days after the first dose]

   maximum tolerated dose

4. RP2D [Up to 21 days after the first dose]

   recommended phase II dose

Secondary Outcome Measures

1. Tmax [up to 2 years]

   Time to Reach Maximum (peak) Plasma Concentration Following Drug Administration

2. Cmax [up to 2 years]

   Maximum Plasma Drug Concentration

3. ORR [up to 2 years]

   Objective Response Rate

4. DCR [up to 2 years]

   Disease Control Rate

5. PFS [up to 2 years]

   Progression-free Survival

6. OS [up to 2 years]

   Objective Response Rate

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF);

2. Age ≥ 18 years when ICF is signed;

3. At least one target lesion as defined per RECIST Version (v) 1.1;

4. Dose escalation phase: Pts with histologically or cytologically confirmed advanced solid tumors, who have failed standard therapy or for whom no standard therapy is available;

5. Dose escalation phase: HR+/HER2-advanced breast cancer that has failed prior CDK4/6 inhibitor combined with endocrine therapy;

6. Eastern Cooperative Oncology Group performance status of 0 or 1;

7. Adequate hematologic and organ function;

8. Female subjects who are not pregnant or breastfeeding

9. Male and female subjects able to have children must agree to use highly effective method of contraception throughout the study and for at least 90 days after last dose.

Exclusion Criteria:

1. Subjects with major cardiovascular and cerebrovascular diseases;

2. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug;

3. Subjects who have received chemotherapy, endocrine therapy, immunotherapy, and targeted therapy, other anti-tumor treatments, or participating in other clinical studies is less than 4 weeks before the first administration of investigational product;

4. Known psychiatric or substance abuse disorders that would interfere with the requirements of the study;

5. HIV-positive or syphilis spiral antibody-positive persons;

6. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks prior to the first dose, or the need for elective surgery during the trial;

7. Known hypersensitivity to the test drug or any of its excipients;

8. History or current evidence of any condition, therapy, or laboratory abnormality, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study, or investigators/sponsor consider the subjects are not suitable for this trial.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army	Beijing	Beijing	China	100039

Sponsors and Collaborators

• Qilu Pharmaceutical Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Qilu Pharmaceutical Co., Ltd.
• ClinicalTrials.gov Identifier: NCT05829616
• Other Study ID Numbers: QLS12004-101
• First Posted: Apr 25, 2023
• Last Update Posted: Apr 25, 2023
• Last Verified: Apr 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Neoplasms

Study Results

No Results Posted as of Apr 25, 2023